SEC Form 4 · accession 0001209191-17-040847
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Klausner
Director
Period of report
Jun 16, 2017
Accepted (ET)
Jun 19, 2017 · 4:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $23.29 | Jun 16, 2017 | A | 12,000 | A | — | Jun 15, 2027 | Common Stock | 12,000 | 12,000 | D |
Explanation of responses
- F1100% of the shares subject to the option become vested and exercisable on the earlier of (i) the date of the 2018 Annual Meeting of Stockholders and (ii) the first anniversary of the grant date, in either event, subject to the director continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through such date.